<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308216">
  <stage>Registered</stage>
  <submitdate>14/07/2009</submitdate>
  <approvaldate>4/08/2009</approvaldate>
  <actrnumber>ACTRN12609000655246</actrnumber>
  <trial_identification>
    <studytitle>Use of aldosterone blockade to improve cardiac function in obesity</studytitle>
    <scientifictitle>Use of aldosterone blockade to improve cardiac function in obesity</scientifictitle>
    <utrn />
    <trialacronym>OB02</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Diastolic Dysfunction</healthcondition>
    <healthcondition>Myocardial fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Spironolactone 25mg
Oral tablets, once a day for a total of 26 weeks.</interventions>
    <comparator>Oral placebo tablet containing lactose, once a day for a total of 26 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Myocardial fibrosis.
Cardiac Magnetic Resonance Imaging (MRI) will be performed on a 1.5 Tesla GE Signa scanner using Electrocardiography (ECG) gating, dedicated cardiac coils, and commercially available software.  Initial localiser sequences are followed by b-SSFP cine sequences in the vertical long axis, horizontal long axis, and left ventricular short axis.  A comprehensive functional study will be performed followed by myocardial characterisation with T1 and T2 weighted imaging, quantification of T2*. Following this resting myocardial perfusion will be assessed following administration of intravenous contrast (containing Gadolinium), then delayed contrast enhanced MRI will be performed to assess fibrosis.</outcome>
      <timepoint>Baseline and post intervetion (26 weeks)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Diastolic function.
A resting echo will be performed using a commercially available Vivid 7.  A variable-frequency phased array transducer will be used for all two-dimensional, M-mode and Doppler examinations.  Tissue Doppler/strain:  Color myocardial tissue Doppler will be obtained with frame-rates set at &gt;110 frames/sec, with a pulse repetition frequency between 500Hz to 1KHz, resulting in aliasing velocity &gt;16 cm/sec.  Digital storage of three sequential cardiac cycle loops triggered to the QRS complex will be saved to magneto-optical disk for off-line analysis of backscatter and strain.</outcome>
      <timepoint>Baseline and post intervetion (26 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemistry.
Collagen biomarkers (PICP, PINP, PIIINP) will be measured by immunoassay as surrogate measures of myocardial fibrosis.</outcome>
      <timepoint>Baseline and post intervetion (26 weeks)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Obesity: Body mass index (BMI) &gt; 30</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Diabetes, cardiovascular disease or other chronic disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Random number-based randomization attached to the study database</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Queensland</primarysponsorname>
    <primarysponsoraddress>St Lucia, Brisbane, QLD 4072</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Centre for Clinical Research Excellence (CCRE)</sponsorname>
      <sponsoraddress>Princess Alexandra Hospital, 4th Floor, blg 1
Ipswich Road, Brisbane Qld 4102</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Obesity is a risk factor for the development of heart failure. Many apparently well obese
subjects have cardiac dysfunction that is detectable with specialized techniques, but which
may contribute to the development of heart failure. There are several potential causes for this
problem, but fibrosis (scarring) of the heart may be an important one. In this study, we plan to
identify whether this can be treated with the aldosterone blocker, spironolactone.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Centres for Health Research
Level 2, Building 35
Princess Alexandra Hospital, Ipswich Rd
Wooloongabba, QLD
4102</ethicaddress>
      <ethicapprovaldate>4/06/2009</ethicapprovaldate>
      <hrec>2009/025</hrec>
      <ethicsubmitdate>10/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>the University of Queensland Medical Research Ethics Committee</ethicname>
      <ethicaddress>The University of Queensland
Cumbrae-Stewart Building
Research Road
Brisbane Qld 
4072</ethicaddress>
      <ethicapprovaldate>6/07/2009</ethicapprovaldate>
      <hrec>2009001186</hrec>
      <ethicsubmitdate>20/06/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Trisha O'Moore-Sullivan</name>
      <address>Diabetes and Endocrinology, Ground Floor, Building 1, Princess Alexandra Hospital
Ipswich Road, Brisbane Qld 4102</address>
      <phone>+61 7 3240 2690</phone>
      <fax />
      <email>t.omooresullivan@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Trisha O'Moore-Sullivan</name>
      <address>Diabetes and Endocrinology, Ground Floor, Building 1, Princess Alexandra Hospital
Ipswich Road, Brisbane Qld 4102</address>
      <phone>+61 7 3240 2690</phone>
      <fax />
      <email>t.omooresullivan@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Stephanie Ipavec-Levasseur</name>
      <address>Ground Floor, R-wing, Princess Alexandra Hospital
Ipswich Road, Brisbane Qld 4102</address>
      <phone>+ 61 7 3240 5114</phone>
      <fax />
      <email>s.levasseur@uq.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>